Long-Circulating Amphiphilic Doxorubicin for Tumor Mitochondria-Specific Targeting

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Mitochondria are key targets in cancer chemotherapy due to their roles in metabolism and apoptosis.
• Doxorubicin is a widely used anticancer drug with limitations in tumor selectivity and cardiotoxicity.

Purpose of the Study:

• To develop a novel molecular approach for enhanced tumor- and mitochondria-selective delivery of doxorubicin.
• To improve the efficacy and safety profile of doxorubicin in cancer treatment.

Main Methods:

• Molecular engineering of doxorubicin by conjugating a lipid tail and a poly(ethylene glycol) polymer to create amphiphilic doxorubicin (amph-DOX).
• In vivo evaluation of amph-DOX for albumin binding, tumor accumulation, circulation time, and cardiac exposure.
• Assessment of intracellular doxorubicin trafficking to mitochondria and its effect on reactive oxygen species (ROS) levels in tumor cells.

Main Results:

• Amph-DOX demonstrated prolonged blood circulation and increased tumor accumulation by utilizing albumin transport pathways.
• Significant reduction in cardiac exposure to doxorubicin was observed with amph-DOX.
• Enhanced mitochondrial targeting of amph-DOX led to increased ROS generation in tumor cells and improved antitumor efficacy compared to unmodified doxorubicin.

Conclusions:

• Amphiphilic modification of doxorubicin is a viable strategy to enhance its anticancer efficacy and safety.
• Hijacking albumin transport and targeting mitochondria represent a dual-action approach for improved chemotherapy.
• This approach offers a simple yet effective method to simultaneously increase doxorubicin's effectiveness and reduce its side effects.